Print

SuppreMol completes successful Pre-IND Meeting with FDA

24.01.2011
SuppreMol GmbH today announced that it has successfully completed a pre-IND meeting with the U.S. FDA for its lead compund SM101.

20110124_SuppreMol PR IND en final.pdf
24 kB

© BioMedPartners 2007top